Zeltia is a former Spanish pharmaceutical company which operated through a variety of subsidiaries in the pharmaceutical and chemical industries. As of 2007, Zeltia's research activities in the pharmaceutical area had not resulted in a marketed product.^{[history 2]} However, the company's majority shareholder and chairman are the same person, which has relieved the pressure which many CEOs have experienced to produce immediate returns.^{[history 3]}

Quick Facts Company type, Traded as ...

Zeltia, S.A.

Company type	Sociedad Anónima
Traded as	BMAD: ZEL
ISIN	ES0184940817
Industry	Pharmaceutical
Founded	Vigo, Galicia, Spain (August 3, 1939 (1939-08-03))
Defunct	2015 (2015)
Headquarters	Madrid , Spain
Area served	Worldwide
Key people	José Fernández Sousa-Faro (Chairman)
Products	Pharmaceuticals
Revenue	US$176 million (2009)
Operating income	(US$46.3) million (2009)
Net income	(US$40.3) million (2009)
Total assets	US$302.9 million (2009)
Total equity	US$59 million (2009)
Subsidiaries	PharmaMar, Genómica, Sylentis, Zelnova, Xylazel
Website	www.zeltia.com
Footnotes / references [finan 1][history 1]

Close

In 1993 Zeltia sells its subsidiary Cooper-Zeltia taking the name CZ Veterinaria, which years later would be renamed Zendal.^[1]

The company was taken over by its subsidiary Pharma Mar in a reverse takeover, keeping the Zeltia's Group structure.

In 2018 PharmaMar sells Xylazel to the Dutch company AkzoNobel.^[2][3]

In 2019 PharmaMar sells Zelnova, the group's last subsidiary in Galicia, to the Galician investment company Allentia Invest for 33 million euros.^[4]

Direct subsidiaries as of 2009 were:^{[finan 2]} Pharma Mar, S.A.U.; Genómica, S.A.U.; Zelnova, S.A; Protección de Maderas, S.A.U; Xylazel, S.A.; Noscira, S.A.; Sylentis, S.A.

Indirect subsidiaries which are direct subsidiaries of Pharma Mar as of 2009 were:^{[finan 2]} Pharma Mar US; Pharma Mar AG; PharmaMar S.A.R.L.; Pharma Mar GmbH; Pharma Mar Ltd.

A single indirect subsidiary is a direct subsidiary of Zelnova, that being Copyr, S.p.A.^{[finan 2]}